NASDAQ:INCY

Incyte Stock Insider Trading

Healthcare > Biotechnology

Buy INCY

*Your capital is at risk

$97.98

+5.74 (+6.22%)

At Close: Jun 03, 2026

Incyte Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.84. In total, the insiders bought 754.56K and sold 443.84K INCY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-62.84
● Buy	754.56K shares
● Sell	443.84K shares
65% Buy Activity Strong Positive Correlation
Buy Signal Low Confidence May 06, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -62.84. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 31, 2026 Buy	Common Stock A-Award	Baker Bros. Advisors Lp	Director	421 Value: $39.6K
Mar 31, 2026 Buy	Common Stock A-Award	Harrigan Edmund Director	Director	269 Value: $25.3K
Mar 31, 2026 Buy	Common Stock A-Award	Clancy Paul J Director	Director	265 Value: $24.9K
Mar 25, 2026 Sell	Common Stock F-InKind	Trotta Matteo EVP, Gm, Dermatology Us	Officer	537 Value: $49.5K
Mar 17, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	7 166 Value: $438.4K
Mar 17, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	11 501 Value: $738.9K
Mar 17, 2026 Buy	Common Stock M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	11 501 Value: $738.9K
Mar 17, 2026 Buy	Common Stock M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	7 166 Value: $438.4K
Mar 17, 2026 Sell	Common Stock S-Sale	Cagnoni Pablo J President, R&d	CEO / President	18 667 Value: $1.76M
Feb 19, 2026 Buy	Common Stock M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	13 093 Value: $808.6K
Feb 19, 2026 Buy	Common Stock M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	5 575 Value: $341.1K
Feb 19, 2026 Sell	Common Stock S-Sale	Cagnoni Pablo J President, R&d	CEO / President	18 668 Value: $1.88M
Feb 19, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	5 575 Value: $341.1K
Feb 19, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Cagnoni Pablo J President, R&d	CEO / President	13 093 Value: $808.6K
Feb 02, 2026 Sell	Common Stock F-InKind	Heeson Lee EVP, Head Of Incyte Intl	Officer	111 Value: $11.4K
Feb 02, 2026 Sell	Common Stock F-InKind	Morrissey Michael James EVP, Head Of Tech. Operations	Officer	185 Value: $19.0K
Jan 20, 2026 Sell	Common Stock F-InKind	Morrissey Michael James EVP, Head Of Tech. Operations	Officer	429 Value: $44.0K
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Tray Thomas Principal Accounting Officer	Officer	2 425 Value: $257.6K
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Trotta Matteo EVP, Gm, Dermatology Us	Officer	8 542 Value: $907.2K
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Issa Mohamed Khairie EVP, Head Of Us Oncology	Officer	14 237 Value: $1.51M
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Stein Steven H EVP & Chief Medical Officer	Officer	19 932 Value: $2.12M
Jan 16, 2026 Buy	Common Stock A-Award	Heeson Lee EVP, Head Of Incyte Intl	Officer	8 911 Value: $946.4K
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Cagnoni Pablo J President, R&d	CEO / President	28 475 Value: $3.02M
Jan 16, 2026 Buy	Employee Stock Option (right to buy) A-Award	Mayes Patrick A EVP & Chief Scientific Officer	Officer	4 218 Value: $448.0K
Jan 16, 2026 Buy	Common Stock A-Award	Morrissey Michael James EVP, Head Of Tech. Operations	Officer	7 426 Value: $788.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INCYTE CORPORATION

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chr...

Read Full Profile Here